# A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

> **NCT05686980** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 18 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ABBV-552

## Key facts

- **NCT ID:** NCT05686980
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-17
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05686980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05686980, "A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05686980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*